Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Net Margin (2016 - 2026)

Intellia Therapeutics has reported Net Margin over the past 12 years, most recently at 633.49% for Q1 2026.

  • Quarterly Net Margin rose 4134.0% to 633.49% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 597.53% through Mar 2026, up 49376.0% year-over-year, with the annual reading at 608.53% for FY2025, 23197.0% up from the prior year.
  • Net Margin was 633.49% for Q1 2026 at Intellia Therapeutics, down from 400.72% in the prior quarter.
  • Over five years, Net Margin peaked at 6647.52% in Q4 2023 and troughed at 1820.05% in Q2 2024.
  • The 5-year median for Net Margin is 771.63% (2022), against an average of 431.25%.
  • Year-over-year, Net Margin skyrocketed 2310050bps in 2022 and then tumbled -762481bps in 2024.
  • A 5-year view of Net Margin shows it stood at 771.63% in 2022, then surged by 961bps to 6647.52% in 2023, then tumbled by -115bps to 977.29% in 2024, then surged by 59bps to 400.72% in 2025, then plummeted by -58bps to 633.49% in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Net Margin are 633.49% (Q1 2026), 400.72% (Q4 2025), and 760.14% (Q3 2025).